Donald Trump winning the US Presidential election could bode well for most of Corporate India. While the manufacturing sector could gain from the anti-China approach, specifically for the Pharma industry, there are some key positives. According to industry veteran Kiran Mazumdar Shaw, India could be a key beneficiary of the US healthcare reforms.
Kiran Mazumdar-Shaw, Executive Chairperson – Biocon and Biocon Biologics said, “President Trump has always favoured India over China as a strategic ally and his presidency will strengthen trading and diplomatic ties especially in technology, defence & healthcare. I am confident that India’s pharma sector will be recognised as integral to US healthcare reforms for the Trump administration.”
The pharma sector, especially the generics are likely to be in focus after Trump’s victory. India could be beneficiary of any any potential move to reallocate healthcare Budget.
Donald Trump was elected the 47th president of the United States today, completing a remarkable political comeback after four years. With his win in Wisconsin, Trump surpassed the 270 electoral votes needed to secure the presidency. Trump secured 277 electoral votes, while Kamala Harris bagged 224 electoral votes, according to AP.
